>>GAITHERSBURG, Md., April 21 /PRNewswire-FirstCall/ -- BioVeris Corporation (Nasdaq: BIOV - News), announced today that it has retained Lehman Brothers as a strategic advisor. The engagement of Lehman Brothers is part of the company's ongoing plan to explore potential new business arrangements with third parties in key markets, including the approximately $22 billion worldwide clinical diagnostic field.
"We are very pleased that Lehman Brothers is part of our global team as we evaluate strategic business arrangements with multiple third parties," said Samuel J. Wohlstadter, Chairman and Chief Executive Officer. "We believe the opportunities for our proven, proprietary technology are significant. We expect to work with our advisors with the goal of enhancing our capabilities and competitiveness, and maximizing the value of our products and technologies, although we cannot provide assurances that we will successfully identify or complete attractive transactions. We have seen increased interest from several global healthcare companies in our technology and the opportunities that it presents for expanding our business through potential collaborations and other strategic initiatives. Lehman Brothers adds its own experience and unique relationships with leaders in global healthcare companies, including those that compete in the worldwide clinical diagnostic marketplace.">>
snip
BIOV bounced hard from its lows of Tuesday afternoon on this news. Pity, I was gunning for an entry at about $10. Back to watch and wait mode.
Cheers, Tuck |
